IRIS UniCatt

Pane, Marika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.284
NA - Nord America 4.572
AS - Asia 2.397
SA - Sud America 366
AF - Africa 53
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 4
Totale 12.688
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.486
DE - Germania 1.463
IT - Italia 1.221
SG - Singapore 1.128
SE - Svezia 795
CN - Cina 620
IE - Irlanda 374
BR - Brasile 320
FR - Francia 298
ID - Indonesia 238
GB - Regno Unito 203
UA - Ucraina 197
RU - Federazione Russa 180
FI - Finlandia 158
IN - India 118
NL - Olanda 93
TR - Turchia 60
HK - Hong Kong 58
CA - Canada 49
AT - Austria 47
BE - Belgio 45
IR - Iran 36
CZ - Repubblica Ceca 30
ES - Italia 28
CH - Svizzera 25
JP - Giappone 23
CI - Costa d'Avorio 22
PL - Polonia 20
AR - Argentina 19
PA - Panama 15
IL - Israele 14
KR - Corea 14
MX - Messico 14
RO - Romania 14
LT - Lituania 13
MK - Macedonia 13
RS - Serbia 13
EG - Egitto 11
PK - Pakistan 10
AE - Emirati Arabi Uniti 8
MA - Marocco 7
NZ - Nuova Zelanda 7
BD - Bangladesh 6
IQ - Iraq 6
PH - Filippine 6
SK - Slovacchia (Repubblica Slovacca) 6
AU - Australia 5
BG - Bulgaria 5
CO - Colombia 5
DK - Danimarca 5
HU - Ungheria 5
PT - Portogallo 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
BY - Bielorussia 4
CL - Cile 4
GR - Grecia 4
HR - Croazia 4
LK - Sri Lanka 4
LV - Lettonia 4
PE - Perù 4
PY - Paraguay 4
TH - Thailandia 4
TW - Taiwan 4
VN - Vietnam 4
ZA - Sudafrica 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
AM - Armenia 3
DZ - Algeria 3
EC - Ecuador 3
EE - Estonia 3
KE - Kenya 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
SA - Arabia Saudita 3
VE - Venezuela 3
BO - Bolivia 2
BT - Bhutan 2
DO - Repubblica Dominicana 2
GE - Georgia 2
JM - Giamaica 2
LU - Lussemburgo 2
NO - Norvegia 2
UY - Uruguay 2
AO - Angola 1
CR - Costa Rica 1
CY - Cipro 1
GL - Groenlandia 1
GT - Guatemala 1
HN - Honduras 1
JO - Giordania 1
LB - Libano 1
ME - Montenegro 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
Totale 12.684
Salva come PNG Salva come JPEG
Città #
Chandler 993
Singapore 725
Ashburn 477
Dublin 339
New York 258
Jakarta 237
Rome 223
Milan 201
San Mateo 150
Moscow 120
Jacksonville 117
Marseille 104
Helsinki 103
Nanjing 99
Wilmington 93
Nürnberg 91
Boston 90
Los Angeles 83
Princeton 78
Dearborn 77
Ann Arbor 70
Munich 67
Woodbridge 66
Houston 58
Nuremberg 58
Beijing 52
Frankfurt am Main 51
Seattle 50
Bremen 48
Hong Kong 48
Düsseldorf 43
Fairfield 43
The Dalles 43
Nanchang 42
Brussels 37
São Paulo 34
Chicago 33
Palermo 33
Redwood City 33
London 32
Lawrence 31
Boardman 29
Pune 28
Toronto 28
Hebei 27
Brno 26
Lancaster 26
Shanghai 26
Falkenstein 25
Cattolica 24
Detroit 24
Paris 24
Augusta 23
Abidjan 22
Vienna 22
Izmir 21
Jiaxing 21
Kish 21
Norwalk 21
Changsha 20
Jinan 20
Leawood 18
Turin 18
Lauterbourg 17
Portsmouth 17
Redmond 17
Shenyang 17
University Park 17
Washington 16
Columbus 15
Florence 15
Tianjin 15
Bologna 14
Busto Arsizio 14
Council Bluffs 14
Andover 13
Guangzhou 13
Hyderabad 13
Inverigo 13
Naples 13
Zhengzhou 13
Fremont 12
Santa Clara 12
Zurich 12
Belo Horizonte 11
Cambridge 11
Hangzhou 11
Kunming 11
Ningbo 11
Ottawa 11
Seoul 11
Stockholm 11
Brasília 10
Lappeenranta 10
Menlo Park 10
Mountain View 10
Salamanca 10
Skopje 10
Amsterdam 9
Bari 9
Totale 6.612
Salva come PNG Salva come JPEG
Nome #
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 259
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 230
Cortical visual function in preterm infants in the first year. 219
Neurological examination of preterm infants a term equivalent age 201
Neurological examination at 6 to 9 months in infants with cystic periventricular leukomalacia 177
Prognostic value of EEG performed at term age in preterm infants. 166
Performance of Upper Limb module for Duchenne muscular dystrophy 163
Crossed cerebellar atrophy of prenatal onset 158
-Thalamic atrophy in infants with PVL and cerebral visual impairment 150
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. 137
Visual development in prenatal post-haemorragic ventricular dilatation 133
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. 127
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care? 127
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 125
Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation 125
A current approach to heart failure in Duchenne muscular dystrophy 125
Muscle MRI in Becker muscular dystrophy 122
Validation and cross-cultural adaptation of the Italian version of the Pediatric Eating Assessment Tool (I-PEDI-EAT-10) in genetic syndromes 114
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study 110
Salbutamol increases serviva motor neuron (SMN) patients: relevance for clinical trial design 108
Muscle MRI in Becker muscular dystrophy 108
Muscle MRI: Out of the tunnel. 106
Revised upper limb module for spinal muscular atrophy: Development of a new module 106
Congenital muscular dystrophies with cognitive impairment. A population study 104
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 104
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy 103
Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine 102
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study 99
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 98
Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era 98
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 98
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy 97
Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype 96
Predominant distal muscle involvement in spinal muscular atrophy 95
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis 94
-Electroclinical patterns and evolution of epilepsy in the 4p- syndrome 93
24 month longitudinal data in ambulant boys with duchenne muscular dystrophy 93
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 93
MRI: Out of the tunnel. 88
Developmental milestones in type I spinal muscular atrophy 87
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 85
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 84
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 83
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol 82
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 81
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 81
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 81
Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study 81
Histological effects of givinostat in boys with Duchenne muscular dystrophy 78
A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues". 78
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 78
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 77
Assessing floppy infants: a new module 77
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 76
Developmental milestones in type I spinal muscular atrophy 76
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 75
Longitudinal assessments in discordant twins with SMA 75
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 75
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 74
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 74
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 74
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 74
6 minute walk test in duchenne MD patients with different mutations:12 month changes 73
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 73
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 73
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 72
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 71
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 71
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 70
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 69
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 69
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 69
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 68
Pediatric Motor Inflammatory Neuropathy: The Role of Antiphospholipid Antibodies. 68
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 68
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 66
Implicit learning deficit in children with Duchenne muscular dystrophy: Evidence for a cerebellar cognitive impairment? 66
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 66
SEPN1-related myopathies: clinical course in a large cohort of patients 65
Nusinersen in type 0 spinal muscular atrophy: should we treat? 65
Longitudinal natural history in young boys with Duchenne muscular dystrophy 65
Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy? 64
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 64
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 63
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 63
Clinical Variability in Spinal Muscular Atrophy Type III. 63
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 62
New Mutations in NEB Gene Discovered by Targeted Next-Generation Sequencing in Nemaline Myopathy Italian Patients 61
An unusual ryanodine receptor 1 (RYR1) phenotype: Mild, calf-predominant myopathy. 60
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 60
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 59
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 59
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 59
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 58
Development of an academic disease registry for spinal muscular atrophy 58
Duchenne muscular dystrophy: Preliminary experience with sacubitril-valsartan in patients with asymptomatic left ventricular dysfunction 57
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 57
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 56
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy 56
Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. 56
Totale 9.199
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.100
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.100
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020153 0 0 0 0 0 0 0 0 0 0 114 39
2020/2021502 44 43 15 38 47 43 73 12 62 30 90 5
2021/20221.137 80 37 21 110 80 38 23 192 68 67 208 213
2022/20233.072 302 382 200 459 193 393 217 272 385 48 142 79
2023/20242.615 109 462 100 177 102 404 351 102 52 130 270 356
2024/20253.311 124 99 401 243 455 258 229 240 766 420 76 0
Totale 12.952